Developing drugs to improve cognitive function in individuals with Down syndrome
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome
['FUNDING_SBIR_2'] · ILUMINOS THERAPEUTICS, LLC · NIH-10709750
This study is looking at new ways to help people with Down syndrome by testing a special treatment that targets a protein linked to memory problems, with the hope of improving thinking skills and brain health.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ILUMINOS THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-10709750 on ClinicalTrials.gov |
What this research studies
This research focuses on creating selective inhibitors for Dyrk1a, a protein that is overexpressed in individuals with Down syndrome (DS) and is linked to cognitive decline and Alzheimer's-like symptoms. By targeting Dyrk1a, the research aims to prevent or reverse cognitive deficits associated with DS. The approach involves using mouse models to test the effectiveness of these inhibitors in improving cognitive function and reducing neurodegeneration. If successful, this could lead to new treatments specifically designed for individuals with DS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Down syndrome, particularly those experiencing cognitive decline.
Not a fit: Patients without Down syndrome or those who do not exhibit cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option to enhance cognitive function and quality of life for individuals with Down syndrome.
How similar studies have performed: Previous research has shown promise in targeting Dyrk1a to reverse cognitive deficits in mouse models, indicating a potential pathway for successful treatment.
Where this research is happening
TUCSON, UNITED STATES
- ILUMINOS THERAPEUTICS, LLC — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DUNCKLEY, TRAVIS — ILUMINOS THERAPEUTICS, LLC
- Study coordinator: DUNCKLEY, TRAVIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease like pathology